Sign in
Taking people in United StatesPhase 3

Samelisant compared with placebo for daytime sleepiness in narcolepsy

Tests samelisant against placebo for sleepiness in adults with narcolepsy.

Key facts

Who runs it
Suven Life Sciences Limited
Where
Columbia, United StatesSee the site
Trial code
Registry title
A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)
Status
Recruiting
Phase
Phase 3
People taking part
240 people, planned
Started
Sept 2026
Expected to end
19 Dec 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Samelisant
  • Placebo
Record updated
3 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with narcolepsy, with or without cataplexy (sudden bouts of muscle weakness), who have strong daytime sleepiness.

Age
18 Years and older
Sex
All
Disease stage
Narcolepsy Type 1 (with cataplexy) or Type 2 (without cataplexy). For Type 1, cataplexy in the last 3 months and on average ≥4 events per week in the last 2 weeks of the washout period. People not treated for sleepiness need an ESS sleepiness score ≥12. Mean stay-awake test (MWT) time under 12 minutes at Baseline.
Earlier treatment
People taking stimulants, modafinil, oxybates, pitolisant, solriamfetol, bupropion or other narcolepsy treatments must stop them 2 weeks before the Baseline visit. No investigational therapy within 30 days (or 5 half-lives, whichever is longer) before joining.
Biomarker or test result
Body mass index from 18 to 45 kg/m2.

Main reasons for not taking part

  • Usual wake-up after 9 am, sleep under 6 h, or bedtime after 1 am.
  • Drug, alcohol or marijuana use disorder now or in the past 3 months, or caffeine over 600 mg/day.
  • Serious heart rhythm test (ECG) changes, such as QTcF ≥450 msec in men or ≥470 msec in women.
  • Use of sleeping pills, tranquilizers, benzodiazepines, anticonvulsants, certain antihistamine-type drugs or other cataplexy medicines.
  • Shift work, night shifts or travel across > 3 time zones that disrupts sleep.

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Body mass index ranging from 18 to 45 kg/m2 (both inclusive)
  • Narcolepsy with or without cataplexy (Narcolepsy Type 1 [NT1] or Narcolepsy Type 2 [NT2]) based on the International Classification of Sleep Disorders 3-TR/ Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for the diagnosis of narcolepsy
  • For NT1 only, current continuing presence of cataplexy as defined by participant report for the last 3 months and have average of ≥4 weekly cataplexy events during the last 2 weeks of the washout period
  • At the screening Visit and the Baseline Visit, participants who are not on treatment for EDS must have ESS scores ≥12 (as assessed with a look-back period of 1 week)
  • A mean MWT time of <12 minutes across the first 4 sessions at Baseline
  • Willingness to complete the study protocol with full compliance with procedures and sign an informed consent form
  • Able to show compliance with sleep diary entries for at least 5 times/week in the final 2 weeks of the screening Period (non-compliant participants will not be included)

Who cannot take part

  • Use of any investigational therapy within the 30-day period (or 5 half-lives, whichever is longer) prior to enrollment
  • Excessive caffeine (defined as >600 mg/day) use at least 1 week prior to Baseline assessments and during the study
  • If receiving stimulants, modafinil, oxybates, pitolisant, solriamfetol, bupropion or other treatments for narcolepsy, and unwilling or unable to complete weaning 2 weeks prior to Baseline visit (Day 1)
  • Concurrent use of hypnotics, tranquilizers, centrally acting H1 receptor antagonists, benzodiazepines, anticonvulsants, or clonidine, tricyclic antidepressants that have H1-antihistamine properties (clomipramine, protriptyline)
  • History of (within past 3 months) or current substance use disorder involving illicit drugs, alcohol, or marijuana, as per DSM-5-TR criteria. Alcohol and/or recreational drugs use within 24 hours of study visits is strictly prohibited
  • Clinically significant ECG abnormalities. Participants are excluded with a screening ECG Fridericia's correction of QT (QTcF) interval ≥450 msec for men and ≥470 msec for women obtained after 5-minute rest in a supine position using a digital ECG
  • Median habitual wake-up time after 9 am as assessed by sleep diary, habitual sleep time of <6 h and median habitual bedtime past 1 am, as determined by sleep diary entries
  • Nicotine dependence that affects sleep (eg, a participant who routinely awakens at night to smoke)
  • Adjunctive pharmacotherapy directed against cataplexy (including but not limited to venlafaxine, fluoxetine, and gamma hydroxybutyrate) is prohibited
  • An occupation requiring variable shift work, variable wake times, night shifts, frequent overnight travel or expected overnight travel across > 3 time zones during the study which disrupts sleep patterns and working remotely leading to inconsistent sleep duration

Where in United States

  • Bogan Sleep ConsultantsColumbia, United StatesTaking people

About the trial

What the trial wants to find out

The primary objective of this study is to evaluate the effect of Samelisant on excessive daytime sleepiness (EDS) after 12 weeks of treatment. In addition, the study aims to assess its effectiveness in influencing the weekly frequency of cataplexy episodes (sudden bouts of muscle weakness) that occur while the individual remains conscious. Other objectives include examining the impact of Samelisant on attention and alertness, overall quality of life, the spectrum of narcolepsy symptoms, and daily functioning, as well as evaluating its safety profile.

The 2 groups in the trial

  • Samelisant TabletsExisting treatment, for comparison

    Treatment: Samelisant

  • Placebo TabletsPlacebo, for comparison

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 3, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Samelisant Compared to Placebo in Patients With Narcolepsy With or Without Cataplexy
Plain-language title
Samelisant compared with placebo for daytime sleepiness in narcolepsyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
3 September 2026